



London Shared Service

Title: Covid-19 IPC Guidance
Date: 03 May 2022
Author: NHS London Shared Service IPC Team

This briefing summary note is correct at the time of publishing. However, guidance on COVID-19 is subject to regular updates on GOV.UK, please use the hyperlinks to read further.

Contents

People with symptoms of a respiratory infection including COVID-19	2
Monitoring reports of the effectiveness of COVID-19 vaccination	3

People with symptoms of a respiratory infection including COVID-19

Guidance for people with symptoms of a respiratory infection including COVID-19, or a positive test result for COVID-19.

From: **UK Health Security Agency**

Published: 1 April 2022

Last updated: 27 April 2022

Details

As we learn to live safely with COVID-19, there are actions we can all take to help reduce the risk of catching COVID-19 and passing it on to others. These actions will also help to reduce the spread of other respiratory infections. COVID-19 and other respiratory infections such as flu can spread easily and cause serious illness in some people.

Vaccinations are very effective at preventing serious illness from COVID-19, however even if you are vaccinated there is a chance you might catch COVID-19 or another respiratory infection and pass it on to other people.

Contents

1. [Who this guidance is for](#)
2. [People at higher risk of becoming seriously unwell from a respiratory infection, including COVID-19](#)
3. [Symptoms of respiratory infections, including COVID-19](#)
4. [What to do if you have symptoms of a respiratory infection, including COVID-19, and have not taken a COVID-19 test](#)
5. [Children and young people \(aged 18 years and under\) who have symptoms of a respiratory infection, including COVID-19](#)
6. [What to do if you have a positive COVID-19 test result](#)
7. [What to do if you are a close contact of someone who has had a positive test result for COVID-19](#)
8. [Children and young people aged 18 years and under who have a positive test result](#)
9. [Translations](#)

Link to the guidance:

[People with symptoms of a respiratory infection including COVID-19 - GOV.UK \(www.gov.uk\)](https://www.gov.uk/guidance/people-with-symptoms-of-a-respiratory-infection-including-covid-19)

Monitoring reports of the effectiveness of COVID-19 vaccination

Page summary:

Data on the real-world efficacy of the COVID-19 vaccines.

The UK Health Security Agency (UKHSA) is monitoring the effectiveness of the coronavirus (COVID-19) vaccines in the real world as set out in the [COVID-19 vaccine surveillance strategy](#) and has published reports on the impact of the COVID-19 vaccines on:

- symptomatic disease
- hospitalisation
- death
- infection (symptomatic or asymptomatic)

The study on COVID-19 Vaccine Effectiveness against the Omicron BA.2 variant in England, suggests that overall, there was no evidence that vaccine effectiveness against symptomatic disease is reduced following infection with the BA.2 sub-lineage as compared to BA.1. Furthermore, similar rates of waning were observed after the second and booster dose for each sub-lineage. These data provide reassuring evidence of the effectiveness of the vaccines currently in use against symptomatic disease caused by BA.2.

The document was first published on 15 November 2021 and was last updated 28 April 2022.

Change made:

Added 'Effectiveness of AstraZeneca COVID-19 booster vaccination against the Omicron and Delta variants'.

Effectiveness of AstraZeneca COVID-19 booster vaccination against the Omicron and Delta variants.

This study estimates the effectiveness of booster vaccination with AstraZeneca against symptomatic disease and hospitalisation in individuals who were not able to receive mRNA vaccines in the UK. The document is still being peer reviewed.

Link to the document page: [Monitoring reports of the effectiveness of COVID-19 vaccination - GOV.UK \(www.gov.uk\)](#)